Salmon fish protein supplement increases serum vitamin B12 and selenium concentrations: secondary analysis of a randomised controlled trial.

What Was Tested

Researchers studied Copper (Supplement) and Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.

The main aim of the present study was to examine the effect of a fish protein supplement made from by-products from production of Atlantic salmon, on blood concentration of micronutrients.

Why It Was Studied

The study was registered at ClinicalTrials.gov (ID: NCT03764423) on June 29th 2018.

Who Took Part

According to the abstract, 88 adults were involved.

In total, 88 adults were randomised to a salmon fish protein supplement or placebo, and 74 participants were included in the analysis of vitamin D, omega-3, vitamin B12, selenium, folate, zinc, homocysteine and mercury.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Neither the adults nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Groups ran in parallel: each of the adults stayed in one arm throughout.

The researchers conducted an 8-week double-blind parallel-group randomised controlled trial.

What Was Measured

The subject headings attached to it are Dietary Supplements, Fish Proteins, Folic Acid, Micronutrients, Salmo salar, Selenium and Vitamin B 12.

The authors tagged it with the keywords Atlantic salmon, RCT, Sustainability and Vitamin B12.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) and Cyanocobalamin (Vitamin B12) in 88 adults.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (European journal of nutrition), a journal based in Germany.

More context: the Copper (Supplement) compound page and the Cyanocobalamin (Vitamin B12) compound page, all human trials.